company background image
RVPH

Reviva Pharmaceuticals Holdings NasdaqCM:RVPH Stock Report

Last Price

US$0.71

Market Cap

US$10.7m

7D

10.1%

1Y

-79.7%

Updated

12 Aug, 2022

Data

Company Financials +
RVPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RVPH Stock Overview

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.

Reviva Pharmaceuticals Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Reviva Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$0.71
52 Week HighUS$4.66
52 Week LowUS$0.53
Beta0.18
1 Month Change-34.26%
3 Month Change-52.51%
1 Year Change-79.71%
3 Year Change-93.09%
5 Year Changen/a
Change since IPO-92.69%

Recent News & Updates

Shareholder Returns

RVPHUS PharmaceuticalsUS Market
7D10.1%1.1%3.2%
1Y-79.7%1.3%-10.1%

Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: RVPH underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is RVPH's price volatile compared to industry and market?
RVPH volatility
RVPH Average Weekly Movement15.2%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RVPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: RVPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a5Laxminarayan Bhathttps://revivapharma.com

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company’s lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, Parkinson’s disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.

Reviva Pharmaceuticals Holdings Fundamentals Summary

How do Reviva Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
RVPH fundamental statistics
Market CapUS$10.74m
Earnings (TTM)-US$14.94m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RVPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.94m
Earnings-US$14.94m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did RVPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RVPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVPH?

Other financial metrics that can be useful for relative valuation.

RVPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does RVPH's PB Ratio compare to its peers?

RVPH PB Ratio vs Peers
The above table shows the PB ratio for RVPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.1x
CPHI China Pharma Holdings
2.1xn/aUS$11.3m
BMMJ Body and Mind
0.3xn/aUS$10.5m
CNSP CNS Pharmaceuticals
0.7x-5.0%US$10.2m
SNOA Sonoma Pharmaceuticals
1.3xn/aUS$10.2m
RVPH Reviva Pharmaceuticals Holdings
0.5x-2.8%US$10.7m

Price-To-Book vs Peers: RVPH is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.1x).


Price to Earnings Ratio vs Industry

How does RVPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: RVPH is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (2x)


Price to Book Ratio vs Fair Ratio

What is RVPH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVPH PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RVPH's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of RVPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RVPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RVPH's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Reviva Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-2.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVPH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVPH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVPH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RVPH is forecast to have no revenue next year.

High Growth Revenue: RVPH is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RVPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Reviva Pharmaceuticals Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-75.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RVPH is currently unprofitable.

Growing Profit Margin: RVPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RVPH is unprofitable, and losses have increased over the past 5 years at a rate of 75.7% per year.

Accelerating Growth: Unable to compare RVPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RVPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).


Return on Equity

High ROE: RVPH has a negative Return on Equity (-69.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Reviva Pharmaceuticals Holdings's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RVPH's short term assets ($25.3M) exceed its short term liabilities ($3.6M).

Long Term Liabilities: RVPH's short term assets ($25.3M) exceed its long term liabilities ($283.7K).


Debt to Equity History and Analysis

Debt Level: RVPH is debt free.

Reducing Debt: RVPH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RVPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RVPH has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 88.3% each year.


Discover healthy companies

Dividend

What is Reviva Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RVPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RVPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RVPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RVPH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RVPH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average board tenure


CEO

Laxminarayan Bhat (56 yo)

16.25yrs

Tenure

US$600,054

Compensation

Dr. Laxminarayan Bhat, Ph D., serves as the Founder of Reviva Pharmaceuticals Holdings, Inc. since 2006 and has been its Director since 2006 and serves as its President and Chief Executive Officer since Ma...


CEO Compensation Analysis

Compensation vs Market: Laxminarayan's total compensation ($USD600.05K) is about average for companies of similar size in the US market ($USD763.69K).

Compensation vs Earnings: Laxminarayan's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: RVPH's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RVPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Reviva Pharmaceuticals Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Reviva Pharmaceuticals Holdings, Inc.
  • Ticker: RVPH
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$10.745m
  • Shares outstanding: 15.13m
  • Website: https://revivapharma.com

Number of Employees


Location

  • Reviva Pharmaceuticals Holdings, Inc.
  • 19925 Stevens Creek Boulevard
  • Suite 100
  • Cupertino
  • California
  • 95014
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.